Alkem Laboratories has launched drug, Pertuza, in India to improve access to HER2-positive breast cancer treatment. Shares of Alkem Laboratories Ltd ended lower on Monday (September 22) by 1% at ₹5,486 on the NSE.
Alkem Laboratories has launched drug, Pertuza, in India to improve access to HER2-positive breast cancer treatment. Shares of Alkem Laboratories Ltd ended lower on Monday (September 22) by 1% at ₹5,486 on the NSE.